There is a silent enemy that threatens our well-being, everyday, without being noticed, without giving any obvious signs
of its action.

Low-level chronic
inflammation represents
one of the most relevant
challenges for themedicine of the 21stcentury, mainly due toour western lifestyleand is well-defined byresearchers such as

The
SilentKiller

Inflammation is one of the primary mechanisms developed by
Nature to maintain health and immune homeostasis of our bodyagainst the thousand environmental attacks that we receive
every day. When this response is not properly regulated, theconcentration of inflammatory markers rises and remains highleading to a physiological status known as low-level chronicinflammation.
Chronic inflammation is known to be associated with agerelated, metabolic and chronic conditions such as cardiovasculardiseases, diabetes and neurological disorders. Since there is nopain associated with this type of physiological response, nothingis done to stop it and thus it can linger for years, if not decades,
causing continual organ challenge.

The silent challenge virtually affects the entire span of our lives.
It is not reasonable to expect to face it through the systematicand continuous use of allopathic medicines, not free from sideeffects, especially on the medium / long term.
But now there’s a life long control strategy more compatible
with our body’s operating modes:

Long Term Life
MaintenanceThe big challenge for MERIVA® is that,
thanks to its proven features, it canrepresent a reference model for a new
type of relationship between turmericand the personal project of Long Term
Maintenance of our lives.
Nowadays, more than ever, the roots of our life seem
to open up to new frontiers in which the maintenanceof our health plays an increasingly important role,
inducing the sciences to a great deal of reflection onproducts, processes and relationships.

MERIVA® is able to help us in controlling,
throughout our entire life, that the natural
inflammatory response does not turninto low-level chronic inflammation.

Thanks to its patented Phytosome® technology- which embeds the 3 fundamental curcuminoids
in a phospholipidic formulation - the systematic
supplementation with MERIVA® fosters the maintenance of“healthy level” of inflammation. This effect is validated by
the most powerful set of clinical analysis conducted in vivo
on human available on the market.

MERIVA® contains all 3 TURMERIC'S CURCUMINOIDS
MCC

LECIT
HIN

RCUMINOID
UCS

ARYET
DI

CURCUMINOIDS

AUC (ng/mL)

Cmax (ng/mL)

AUC (ng/mL)

Cmax (ng/mL)

Relative
Absorption*

Curcumin538.0 ± 130.7

50.3 ± 12.7

122.5 ± 29.3

9.0 ± 2.8

19.2

Demethoxycurcumin

655.0 ± 195.7

134.6 ± 40.6

55.8 ± 15.5

4.2 ± 1.1

68.3

Bisdemethoxycurcumin

142.2 ± 58.2

24.9 ± 8.1

24.6 ± 10.3

2.1 ± 0.8

56.8

TOTAL CURCUMINOIDS

1336 ± 357.1

206.9 ± 54.9

202.8 ± 53.8

14.4 ± 4.2

31.5*Normalized AUCs, expressed in ng/mL (plasma) x h/mg ingested, were divided by the AUC value of the reference to calculate the relative absorption values

The Phytosome® technology
on which MERIVA® has beenformulated is based ona biomimetic design concept.

The Phytosome
technology®

The Phytosome® technology draws the energy
from the belief that mimicking Nature, remaking
it with the brainpower of researchers by buildingprocesses and principles on the laboratory
bench,

ytohP

explanationsome®

teology | A bnrchfie

is aimed to achieve benefits
in terms of rationalization,
simplification, sustainability,tolerability and security ofpeople. That is crucial in aLong Term Life Maintenanceperspective.

The biomimetic approach for Indena is the way torespond to the changing needs of human beings,
to explore the potential of the future and support
partners and customers towards new futures.

Not a simple label capable ofembellishing but a real scientific
gem since 90 years!

Indena usedfor MERIVA®

The strength of the biomimicry
concept is that Nature is seen asa model, measure and mentor bywhich to judge the appropriatenessof our technological innovations.
Biomimicry is the art and science of observing theliving world, distilling strategies that stand the test oftime and applying these deep principles to our humanchallenges.
• Nature’s 4-billion-year-old R&D lab offers abottomless treasure-trove of energy efficient,
low-toxic and time-tested innovations.

deIn• Biomimicry has become a widely recognized,
comprehensive methodology for innovation inindustries as diverse as agriculture, architecture,manufacturing, transportation, healthcare, software,materials and robotics.

na | Values• Nature-inspired solutions are everywhere andwe can expect them to explode in the coming years.

What’s in it
for you
According to estimates from Nutrition Business
Journal (NBJ), sales of turmeric reached $196
million in 2015, up 20% from the previous year
and are projected to reach $433 million by 2020.
Turmeric was the top-selling ingredient in theherb category for 2016, according to SPINSdata, earning about $42.2 million in the naturalchannel, up 36.7% from 2015.

How would MERIVA®
support your business
Imagine how the effectiveness of MERIVA® asLife Guardian™ in a life maintenance & longevity
personal project should:_Enlarge_IncreaseYour prospect target to non-pathologic situation.

The average consumption per capita.

_Widen_Strengthen

The consumption window either in terms of consumerage (aging – longevity – prevention) or in occasions ofconsumption.

Your customers brand advocacy and fidelization: Indena will
deploy a strong communication and divulgative program
about MERIVA® Life Guardian™ properties.

EndorsementMERIVA® was independently
endorsed by the prestigious
Cleveland Clinic in the US as
the curcumin formulation ofchoice.

ScientificEvidence
The peer reviewed science on MERIVA®.
MERIVA® still stands as the most pre-clinically and clinically
documented curcumin bioavailable formulation.

Animal pharmacokinetics studies

1

Pre-clinical and veterinary studies

7

Total human published clinical trials

29

Human pharmacokinetic study

1

Sports nutrition and muscular preservation3

Supportive care6

Eye health5

Joint health3Pain relief

3Diabetes related challenges

2

Skin challenges

1BPH

1Liver health

2Bone health2

Total subjects enrolled in controlled trials

SafetyICH 90 days toxicological trial – available (MERIVA® is safe!)
ICH 90 = acute safety study
Human Study: clinical ophthalmological trial (106 patients),
MERIVA® was administered at a daily dosage of 1.2 g/day forup to 18 months withouth causing discomfort or significant
side effects and 0 drop out (Allegri et al. manuscript inpreparation)

Human Study Evidence
Joint health human validation in an 8-month period
WOMAC score: fm 80.6 a 33.3 = 58% decrease
SEI (Social & Emotional Index) score : > 3-fold improvement
TREADMILL: > 4-fold increase (p<0.05)
CRP (C-Reactive Protein) 16-fold decrease (p<0.05)

2000

Human Study Evidence
MERIVA® AND JOINT CHALLENGE: productevaluation registry study 2
CRP variations
Treatment
Inclusion

Controls

168 (SD18) mg/Lt

8 Month10.2 (SD 3.51)*

175 (12.3)
132 (18.2)*p<0.05 (Mann Whitney) SOURCE: ALT. MED. REV. 2010, 15, 337-344

Human Study EvidenceControls

Decrease in use of medications/painkillers

63%

13%

Decrease in gastrointestinal challenges

69%

15%

Decrease in use of other treatments

38%

11%

Distal management costs

49%

3%

Distal edema decrease

65%

5%

Hospital admissions, consultation and tests decrease

38%

6%

Specific decrease in non-drug treatment(i.e. Physiotherapy), costs due to different
complications, new consultations, tests et cet.

44%

8%

Human Study Evidence

MERIVA® ONSET

Liver metabolic challenge

4.0

Supplementation with MERIVA® was associatedwith a reduction in serum levels of:Treatment ATreatment BMERIVA® 2.0g

3.53.02.5
2.0
1.5

Total cholesterol (p<0.001)-21%

LDL-C (p<0.001) 		

-23%

Triglycerides (p<0.001)-17%

Non-HDL-C (p<0.001)-26%

Uric acid (p<0.001)

-8%

1.0

Serum levels of HDL-C and glucose control parameters remained unaltered,suggesting that the MERIVA® supplementation reduces serum lipids and uricacid concentrations in subjects with NAFLD. MERIVA® was safe and welltolerated during this study

0.5
0.0
T0

0.5

12

364

81224

SOURCE: J. CARDIOVASC. PHARMACOL. 2016; 68:223–229

Time (hours)

Human Study Evidence
BONE DENSITY CHANGES (in percentage from initialvalues) in small finger bone density
8Change in small finger bone density (%)

ScoreMERIVA®

SourceEuropean Review for Medical and Pharmacological Sciences

765432
Standard management

10

Standard management+ MERIVA®
4 weeks

12 weeks

24 weeks

Effects of a curcumin-based
supplementation in asymptomatic
subjects with low bone density:a preliminary 24 week
supplement study
P. Riva, S. Togni, L. Giacomelli, F. Franceschi, R. Eggenhoffner,B. Feragalli, G. Belcaro, M. Cacchio, H. Shu, M. Dugall

Bibliography
Issue

Impact Factor 16/15

Age of Subjects

N°(m/f) Treated with MERIVA®

J. Nat. Prod. 2011. 74(4): p. 664-9

3,28135 ± 109 (8/1)

Altern. Med. Rev. 2010. 15(4): p. 337-44

3.00

43.6 ± 5.5

50 (23/27)

Panminerva Med. 2010. 52 (2 Suppl 1): p. 55-62

1,698

44.4 ± 7.2

23 (12/11)

Eur. Rev. Med. Pharmacol. Sci. 2014. 18(24): p. 3959-63

1,778

56.6 ± 4.763 (31/32)

Eur. Rev. Med. Pharmacol. Sci. 2017. 21(7): 1684-1689

1,778

71.0 ± 2.129 (13/16)

Clin. Ophthalmol. 2010. 4: p. 1201-6

N.A.

37.0 ± 4.7

122 (68/54)

Clin. Ophthalmol. 2012. 6: p. 801-6

N.A.

range 29-68

12 (12/1)

Clin. Ophthalmol. 2013. 7: p. 939-45

N.A.

range 29-68

12 (12/1)

Minerva Oftamol. 2016. 58: p. 1-5

N.A.

58 ± 7

12 (3/9)

Int. J. Ophthalm. Clin. Res. 2014 1:002

N.A.

range 66-84

20Panminerva Med. 2012. 54(1 Suppl 4): p. 17-22

1,698

J. Pain Res. 2013, 6, 201-205

2,581

50.07 ± 12.67

15 (7/8)

J. Pain Res. 2013, 6: p. 497-503

2,581

range 50-66

141

Evid. Based Complement. Alternat. Med. 2014: p. 891310

1,740

57.9 ± 14.8

180 (44/136)

Panminerva Med. 2011. 53(3 Suppl 1): p. 43-9

1,698

Panminerva Med. 2012. 54(1 Suppl 4): p. 11-6

1,698

55.2 ± 2.1

38 (21/17)

J. Int. Soc. Sports Nutr. 2014. 11: p. 31

2,066

32.7 ± 12.3

10 malesJ. Int. Soc. Sports Nutr. 2015. 12(1): p. 5

2,066

35.5 ± 5.7

11 malesEuropean Review for Medical and Pharmacological Sciences 2016; 20: 762-766

1,778

74 ± 1 - 73 ± 1

31 (17/14); 22(10/12)

BioMed. Research International, vol.2015, Article ID 283634

2,476

37 (19-62)

31 (14/17)

J. Cardiovasc. Pharmacol. 2016; 68: 223-229

2,462

44.98 ± 12.59

44 (24/20)

Drug Res. 2017; 67: 244-251

0,701

44.98 ± 12.59

44 (24/20)

Allergy Asthma Proc. 2016; 37: e8-e13

2,709

11.1 ± 3.3

15 (11/4)

Indena S.p.A. Viale Ortles 12 - 20139, Milan, Italy
Please note this documentation is available for various countries all over the world and hence it may contain statements or product classi cation not applicable to yourcountry. The claims made are in reference to ingredients only, hence they do not refer to finished products and they may not comply with Regulation EC n. 1924/2006. The
marketer of any finished product containing any ingredient is responsible for assuring that the destination of the product and the claims made for the finished product arelawful and comply with all applicable laws and regulations of the country or countries in which the product is to be sold.